Glucose Metabolism Disorders
Conditions
Brief summary
The risk version of the MTNR1B gene (which codes for a melatonin receptor) has been associated with type II diabetes (T2D) and associated physiological markers. People with the risk version of the gene have reduced secretion of insulin when melatonin levels are high (between evening and morning) and impaired glucose tolerance when they eat late. Previous research suggests eating a protein enriched breakfast can improve glucose response. Therefore, the present study will investigate if the version of the MTNR1B gene that people have is associated with their glucose response after breakfast. Also, whether a protein enriched breakfast improves glucose response in participants with the risk version of the gene. Measures of glucose response collected over the two-week duration of the study will be compared between groups with the different versions of the gene. These findings can be used to provide personalised nutrition advice which may reduce the risk of T2D.
Interventions
DIETARY_SUPPLEMENTBreakfast
Breakfast in one condition will be high carbohydrate and in the other protein enriched
Sponsors
St. Mary's University, Twickenham
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Masking description
Breakfast condition - high carbohydrate or protein enriched
Eligibility
Sex/Gender
ALL
Age
18 Years to 48 Years
Healthy volunteers
Yes
Inclusion criteria
* aged 18-48 years\*, not diabetic, not sleep disorder, not relevant medication (weight loss, sleeping, melatonin), not restricted diet, not allergic to oats, milk, wheat, barley or soya, not implanted medical device, such as pacemakers.
Exclusion criteria
* aged \< 18 or \> 48 years, diabetic, sleep disorder, eating disorder, taking relevant medication (weight loss, sleeping, melatonin), following a restricted diet, implanted medical device, such as pacemakers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose response | 120 minutes | Area under the curve |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CGM metrics - mean glucose | 14 days | mean glucose for 14 days measured using (FreeStyle Libre Pro iQ Continuous Glucose Monitoring System) |
| CGM metrics - Time in range | 14 days | Time in range for 14 day period (FreeStyle Libre Pro iQ Continuous Glucose Monitoring System) |
| CGM metrics - glycaemic variability | 14 days | glycaemic variability for 14 day period (FreeStyle Libre Pro iQ Continuous Glucose Monitoring System) |
Countries
United Kingdom
Outcome results
None listed